Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TKI Discontinuation Feasible After ALL Treatment

2.

Breast cancer: Why it's difficult to treat and what new approaches are on the horizon

3.

The need for more Latinx participants in Alzheimer's trials is urgent.

4.

Triplet Could Become a New Standard in Tough-to-Treat CLL

5.

November 2023, Medical Bulletin 04/.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot